Rodec Pharma Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Rodec Pharma Limited's is preparing to launch its Initial Public Offering (IPO) with a substantial issue size of 56,50,000 Shares. The offering comprises a fresh issue component of TBD.
The price band for the IPO has been set at TBD, providing investors with a range to place their bids. The minimum investment lot consists of TBD, making it accessible to both retail and institutional investors.
The subscription window for this public offering opens on TBD and will conclude on TBD. Following the subscription period, the share allotment is scheduled for TBD, with the official listing expected to commence on TBD on the NSE, BSE exchange.
Rodec Pharma Ltd., incorporated in 1997, operates in the animal healthcare sector, focusing on manufacturing animal feed supplements and marketing veterinary pharmaceutical products. The company follows an integrated business model that includes production, distribution, and marketing, allowing it to reach customers across multiple regions in India. Its product portfolio includes around 35 products with 29 variants such as antibiotics, antispasmodics, ectoparasiticides, and nutritional supplements. With a wide distribution network covering many states and a workforce of over 600 employees, the company has established a strong presence in the veterinary and livestock healthcare market.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Focused Pharmaceutical Business: Engaged in manufacturing and supplying pharmaceutical products, supporting consistent demand from the healthcare sector.
- Diverse Product Portfolio: Offers a range of formulations across therapeutic segments, reducing dependency on a single product line.
- Growth Potential in Healthcare Sector: Rising demand for medicines and healthcare products supports long-term business expansion.
- Regulatory Compliance Risk: Subject to strict pharmaceutical regulations, and any non-compliance can impact operations.
- Working Capital Intensive: Requires continuous investment in raw materials, production, and distribution, affecting cash flow cycles.
- Competitive Industry: Faces strong competition from established pharma companies, which can pressure pricing and margins.
- Mukesh Kumar Gupta
- Chhaya Gupta
- Utkarsh Gupta
Rodec Pharma Limited
Bigshare Services Private Limited